AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research note issued on Tuesday.
A number of other brokerages have also commented on AZN. UBS Group restated a “neutral” rating and set a GBX 5,600 ($73.17) price objective on shares of AstraZeneca in a report on Monday, July 2nd. Deutsche Bank dropped their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 5,700 ($74.48) and set a “buy” rating on the stock in a report on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 25th. Finally, Barclays set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, July 27th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of GBX 5,705.70 ($74.56).
Shares of LON AZN opened at GBX 5,864 ($76.62) on Tuesday. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Google Finance Portfolio Workaround
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.